DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (NYSE Amex: NEOP) announced today that it received on March 18, 2011 from Platinum Montaur Life Sciences, LLC (“Platinum”) a notice attempting to nominate three persons as directors of Neoprobe Corporation (“Neoprobe”) at Neoprobe’s 2011 annual meeting of stockholders, and stating that it may attempt to solicit proxies for the election of these persons as directors at the annual meeting. On the same date, Platinum, along with its affiliate Platinum Partners Value Arbitrage Fund L.P. (together, the “Reporting Persons”), filed with the United States Securities and Exchange Commission (“SEC”) a Schedule 13D stating Platinum had submitted the director nominations, and that the Reporting Persons may solicit proxies to vote common stock of Neoprobe in support of the election of these persons and in support of other proposals the Reporting Persons may make regarding management, capital allocation policies and governance of Neoprobe.
